Cell Genesys, Inc. - Sales Analysis Snapshot

Business Description
This Report provides a comprehensive Sales & Margin summary analysis for Cell Genesys, Inc. Tabular results include up to a ten-year history on Sales, EBITDA (Earnings before Interest, Taxes, Depreciation and Amortization), Income before Extraordinary Items and number of Employees. Additional ratios are included for sales growth, earnings and income as a percent of sales and Sales per Employee.

Cell Genesys, Inc.. The Group's principal activities are researching, developing and commercializing novel biological therapies for patients with cancer. It currently has three product platforms: GVAX cancer vaccines, oncolytic virus therapies and cancer gene therapies. The Group conducts clinical trials in multiple types of cancer utilizing its GVAX cancer vaccines and oncolytic virus therapy product platforms. GVAX vaccines consist of irradiated tumor cells, genetically modified to secrete a hormone that stimulates the body's immune response to vaccines. Oncolytic virus therapies which employ genetically modified adenoviruses are engineered to selectively replicate in and kill cancer cells.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report